Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 4/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851065 | 0.81 | CA12 (0.31) | — | |
| SCHEMBL30636770 | 0.81 | SLC7A5 (0.33) | LAP3FDPSANPEP | |
| SCHEMBL11304670 | 0.68 | LAP3 (0.41) | LAP3ANPEPERAP1ERAP2ALDH1A1 | |
| SCHEMBL11299136 | 0.68 | LAP3 (0.41) | LAP3ANPEPERAP1ERAP2ALDH1A1 | |
| SCHEMBL1582150 | 0.67 | ANPEP (0.40) | LAP3FDPSANPEPERAP1ERAP2 | |
| SCHEMBL1614222 | 0.65 | GABRP (0.33) | — | |
| SCHEMBL1614218 | 0.65 | GABRP (0.33) | — | |
| SCHEMBL19882798 | 0.65 | DPP4 (0.36) | — | |
| SCHEMBL634266 | 0.64 | — | — | |
| D-Alanine SCHEMBL28444494 | 0.64 | SLC7A5 (0.48) | LAP3ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140121366-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2014-05-01 | — | — | US | claimed |
| EP-2432792-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | Pharmasset, Inc. (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3321275-B1 | CRYSTALLINE FORM OF SOFOSBUVIR | GILEAD SCIENCES INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3290428-B1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-105085592-B | N- [ (2' R) -2' -deoxy-2 ' -fluoro-2 ' -methyl-P-phenyl-5 ' -uridylyl ] -L-alanine 1-methylethyl ester and process for preparing same | 吉利德制药有限责任公司 | 2021-04-27 | — | — | CN | disclosed |
| EP-3321275-A1 | CRYSTALLINE FORM OF SOFOSBUVIR | Gilead Pharmasset LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3290428-A1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | Gilead Pharmasset LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20180044367-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-2913337-B1 | PROCESS FOR THE PRODUCTION OF SOFOSBUVIR | GILEAD PHARMASSET LLC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20130165401-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130137654-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2552930-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-2432792-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | Pharmasset, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011123645-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121366-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1723/4885FDPS 795/4885ANPEP 375/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1686/4885FDPS 780/4885ANPEP 359/4885 |
| US-20130137654-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1723/4885FDPS 795/4885ANPEP 375/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1723/4885FDPS 795/4885ANPEP 375/4885 |
| US-20130165401-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1723/4885FDPS 795/4885ANPEP 375/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1686/4885FDPS 780/4885ANPEP 359/4885 |
| US-20180044367-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | LAP3 1723/4885FDPS 795/4885ANPEP 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.